Opus Genetics Inc

NASDAQ:IRDUnited States

Nov 12, 2024

Show headlines and story abstract

• Press Release: Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones

  8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: IRD

• Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones

  8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: IRD
  2024 2023 2024 2023 ----------- ----------- ----------- ----------- License and collaborations revenue $ 3,867 $ 11,935 $ 6,690 $ 17,358 Operating expenses: General and administrative 2,894 2,055 10,918 8,680 Research and development 8,982 3,494 19,817 13,812 ---------- ---------- ---------- ---------- Total operating expenses 11,876 5,549 30,735 22,492 ---------- ---------- ---------- ---------- (Loss) income from operations (8,009) 6,386 (24,045) (5,134) Financing costs -- (1,328) -- (1,328) Fair value change in derivative liability -- 61 -- 61 Other income, net 483 456 1,648 1,224 ---------- ---------- ---------- ---------- (Loss) income before income taxes (7,526) 5,575 (22,397) (5,177) Provision for income taxes -- (14) -- (14) ---------- ---------- ---------- ---------- Net (loss) income (7,526) 5,561 (22,397) (5,191) ---------- ---------- ---------- ---------- Other comprehensive (loss) income, net of tax -- -- -- -- ---------- ---------- ---------- ---------- Comprehensive (loss) income $ (7,526) $ 5,561 $ (22,397) $ (5,191) ========== ========== ========== ========== Net (loss) income per share: Basic $ (0.29) $ 0.26 $ (0.88) $ (0.25) ========== ========== ========== ========== Diluted $ (0.29) $ 0.25 $ (0.88) $ (0.25) ========== ========== ========== ========== Number of shares used in per share calculations: Basic 26,145,080 21,446,648 25,501,117 21,117,211 Diluted 26,145,080 22,405,995 25,501,117 21,117,211 ========== ========== ========== ==========
  

• Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4), from 7:59AM ET on Tuesday Nov 12, 2024 by Dow Jones

  7:59AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: IRD
  
  Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  
  FARMINGTON HILLS, Mich., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other ophthalmological disorders (the "Company"), today announced that the independent members of its Board of Directors approved an equity award under the Company's 2021 Inducement Plan, as amended, as a material inducement to Dr. Benjamin Yerxa, Ph.D., the Company's newly appointed President, in connection with his employment with the Company, effective November 7, 2024. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of any equity awards that are not made under a stockholder approved equity plan.
  

• Press Release: Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4), from 7:59AM ET on Tuesday Nov 12, 2024 by Dow Jones

  7:59AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: IRD
  
  Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  
  FARMINGTON HILLS, Mich., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other ophthalmological disorders (the "Company"), today announced that the independent members of its Board of Directors approved an equity award under the Company's 2021 Inducement Plan, as amended, as a material inducement to Dr. Benjamin Yerxa, Ph.D., the Company's newly appointed President, in connection with his employment with the Company, effective November 7, 2024. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of any equity awards that are not made under a stockholder approved equity plan.